Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Sarcoma 5Carcinoma, Non-Small-Cell Lung 5Rhabdomyosarcoma 4Prostatic Neoplasms 4Osteosarcoma 3Neoplasms 3Sarcoma, Synovial 2Sarcoma, Ewing 2Neuroectodermal Tumors, Primitive, Peripheral 2Neoplasm Metastasis 2Lung Neoplasms 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Adrenocortical Carcinoma 2Wilms Tumor 1Uveal Melanoma 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Retinoblastoma 1Rectal Neoplasms 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive 1Neuroectodermal Tumors 1Neuroblastoma 1Mesothelioma, Malignant 1Liver Neoplasms 1Liposarcoma 1Leiomyosarcoma 1

Interventions

Bevacizumab 69Sorafenib 66lenvatinib 59durvalumab 38sintilimab 33Nivolumab 32tislelizumab 28atezolizumab 28pembrolizumab 27Oxaliplatin 26tremelimumab 23apatinib 22Fluorouracil 22Radiosurgery 20regorafenib 19camrelizumab 18Doxorubicin 18cabozantinib 16Leucovorin 16Capecitabine 16Radiotherapy 14Folfox protocol 14donafenib 13Gemcitabine 13Cisplatin 12toripalimab 11Erlotinib Hydrochloride 10spartalizumab 8anlotinib 8Neoadjuvant Therapy 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Hepatocellular × cixutumumab × Clear all
NCT00906373 2018-06-04

A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver

Eli Lilly and Company

Phase 2 Completed
47 enrolled 14 charts
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT00639509 2014-05-23

IMC-A12 in Treating Patients With Advanced Liver Cancer

National Cancer Institute (NCI)

Phase 2 Completed
24 enrolled 8 charts
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡